Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Quest DiagnosticsNearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest DiagnosticsCompanies: Quest DiagnosticsStudy published in JAMA Network Open of over 193,000 patients nationwide reveals that individuals with evidence of exposure to Borrelia burgdorferi, the bacterium that causes Lyme disease, are more than four times as likely to have antibodies against other tick-borne pathogens compared to...
- Serbian Biotech Startup Takes Its Journey from Belgrade to Cambridge with Documentary on Longevity ScienceBELGRADE, Serbia, September 21, 2026--BioEridan, a Serbian biotechnology startup backed by Telekom Srbija Group’s TS Ventures Fund, has premiered a new documentary showcasing its development of underwater Aquafarms and its ambition to contribute to the next generation of longevity science.
- ScitaraScitara Sets New Strategic Direction, Names Mike Tarselli Chief Strategy Officer to Lead Expansion into Lab IntelligenceMARLBOROUGH, Mass., September 21, 2026--Scitara, the Lab Connectivity and AI platform company serving the life sciences and biopharma industries, today announced a new strategic direction for the company alongside the appointment of Mike Tarselli, Ph.D., MBA, as Chief Strategy Officer. The moves mark Scitara's evolution from a lab connectivity provider into a multi-vendor lab intelligence company.
- Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)DUBLIN, September 21, 2026--Alkermes plc (Nasdaq: ALKS) today announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company’s novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of attention-deficit hyperactivity disorder (ADHD). The study evaluated the safety and tolerability (primary objective) and pharmacokinetics (PK) and pharmacodynamics (PD) of ALKS 7290 in healthy volunteers (n=88) and in adults with ADHD (n
- Iambic Launches Enchant v3 – Molecular Superintelligence Designed to Advance End-to-End Drug Discovery & DevelopmentSAN DIEGO, September 21, 2026--Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven platform, today unveiled Enchant v3, the next generation of its multimodal transformer model built to advance end-to-end drug discovery and development. Enchant is the ‘brain’ behind Iambic’s molecular superintelligence platform that, when combined with Iambic’s in-house high-throughput experimental chemistry and biology capabilities, can learn from and predi
- Global $16.8 Billion Industrial Ventilation Systems Market Forecast, 2036 | Demand for Advanced and Highly Efficient Ventilation Solutions is EscalatingAxial fans, general ventilation, large enterprises, and manufacturing lead the market, while fume extractors, spot ventilation, pharmaceuticals, and Asia-Pacific offer strong growth opportunities. IoT- and AI-enabled ventilation systems are also accelerating adoption.
- $4.1 Billion Industrial Humidifiers Market Forecast, 2036Isothermal and duct-mounted humidifiers lead the market, while healthcare and pharmaceuticals are the fastest-growing application. Europe leads globally, with Asia-Pacific forecast to grow fastest.
- Global Automated Cell Culture Market Assessment 2026, Set to Reach USD 56.1 Billion by 2033 - Biologics and Cell/Gene Therapies Demand Scalable, Reproducible Production, Creating Opportunities in Instruments and ConsumablesAI- and robotics-enabled cell culture is gaining traction as biologics and cell/gene therapies demand scalable, reproducible production, creating opportunities in instruments and consumables
- Global Conjugation and Labeling Services Market to Reach USD 2.4 Billion by 2033: Biologics, Precision Medicine and Outsourcing Demand AcceleratePrecision medicine, advanced diagnostics and ADCs are driving outsourced custom conjugation, novel labels and automation, with opportunities in emerging markets
- Global Microfluidics Market Assessment 2026: Set to Expand Through 2033 as Point-of-Care Diagnostics, Drug Discovery and Lab-on-a-Chip Innovation Drive New Growth OpportunitiesDemand for rapid diagnostics, personalized medicine and drug screening is driving microfluidics, creating opportunities in lab-on-chip, wearables, AI automation and emerging markets
- Global Wearable Biosensors Market Trends, Strategies and Forecast to 2036 Featuring Abbott Labs, Dexcom, Medtronic, Roche, Apple, Samsung Electronics Co., Garmin and Other Key PlayersCompanies: DexcomGarmin Ltd.Medtronic plcRoche HoldingSamsung Electronics"Wearable Biosensors Market - Global Forecast to 2036" has been added to ResearchAndMarkets.com's offering. According to the research report, the global wearable biosensors market is projected to reach USD 105.5 billion by 2036 from USD 35.5 billion in 2026, growing at a CAGR of 12.5% during the forecast period (2026-2036). The growth of this market is primarily driven by the escalating demand for continuous health monitoring, the rising prevalence of chronic diseases such as diabetes and cardiovascular conditions, and the increasing adoption of personalized healthcare solutions. Wearable biosensors are sophisticated devices that enable real-time tracking of physiological parameters, providing critical data for early disease detection and remote patient management. The global wearable biosensors market is undergoing a profound structural transformation as the healthcare industry shifts from episodic, clinic-based care toward continuous, proactive health management. This evolution is being catalyzed by the rapid miniaturization of sensing technologies and the integration of advanced data analytics and artificial intelligence into consumer wearables. The industry is witnessing a significant transition from simple activity trackers toward medical-grade diagnostic devices that can monitor complex biomarkers like glucose, blood pressure, and cardiac rhythms with high precision. Furthermore, the integration of wearable biosensors with digital health and telemedicine platforms is creating a seamless ecosystem for remote patient monitoring and virtual care delivery. This dynamic shift ensures sustained demand for non-invasive, user-friendly sensing solutions that empower individuals and healthcare providers with actionable health insights, ultimately improving clinical outcomes and reducing healthcare costs. Market Segmentation The global wearable biosensors market is segmented by biomarker type (glucose monitoring, heart rate and cardiac biomarkers, blood oxygen [SpO2] monitoring, blood pressure monitoring, lactate and performance biomarkers, and other biomarkers), product type/form factor (smartwatches, fitness bands, continuous glucose monitoring devices, wearable ECG monitors, smart patches, smart rings, and smart clothing), application (clinical and medical, fitness and wellness, and sports and performance monitoring), end-user (hospitals and clinics, home care settings, fitness and sports organizations, individual consumers, and research institutions), and geography. The study evaluation includes industry competitors and analyzes the market at the country level. Based on Biomarker Type By biomarker type, the glucose monitoring segment is expected to hold the largest share of the global wearable biosensors market in 2026. This dominance is attributed to the high and rising prevalence of diabetes globally and the widespread adoption of continuous glucose monitoring (CGM) systems that eliminate the need for frequent finger-prick testing. Conversely, the heart rate and cardiac biomarkers segment is projected to register significant growth, driven by the increasing integration of ECG and heart rate variability (HRV) sensing into consumer smartwatches, enabling early detection of arrhythmias and other cardiovascular conditions. Furthermore, the lactate and multi-analyte biosensors segments are projected to register the highest CAGR during the forecast period, fueled by the growing demand for performance optimization in sports and the development of non-invasive sensors for comprehensive metabolic health tracking. Based on Product Type / Form Factor By product type/form factor, the smartwatches with integrated biosensors segment is expected to hold the largest share of the global wearable biosensors market in 2026. Smartwatches have become the primary platform for health monitoring due to their high consumer acceptance, multi-functionality, and the continuous addition of medical-grade sensors by leading tech companies. Meanwhile, the continuous glucose monitoring devices segment is projected to register the highest CAGR during the forecast period. This rapid growth is driven by the shift toward proactive diabetes management and the expansion of CGM use among non-insulin-dependent patients and health-conscious individuals. Additionally, smart patches and smart rings are emerging as high-growth segments, offering discrete and specialized monitoring for clinical and wellness applications. Based on Application By application, the clinical and medical segment is expected to hold the largest share in 2026. The increasing use of wearable biosensors for chronic disease management, post-operative monitoring, and clinical trials drives this segment's leadership. Within this segment, remote patient monitoring (RPM) is a major growth catalyst. Conversely, the fitness and wellness segment is projected to register a steady growth rate, driven by the increasing consumer focus on preventive health and the popularity of activity and sleep tracking. The sports and performance monitoring segment is also witnessing rapid expansion as professional athletes and fitness enthusiasts adopt biosensors to optimize training and recovery through data-driven insights. Based on End-User By end-user, the hospitals and clinics segment is expected to hold the largest share in 2026, reflecting the primary role of healthcare providers in prescribing and managing medical-grade wearable sensors for patient care. Conversely, the home care settings segment is projected to register the highest CAGR during the forecast period. This rapid growth is driven by the global trend toward decentralized healthcare and the increasing preference for monitoring patients in their home environments to improve comfort and reduce hospital readmissions. The individual consumers segment also remains significant, as more people purchase wearables for personal health and fitness tracking. Geographic Analysis In 2026, North America is expected to account for the largest share of the global wearable biosensors market. The region's leadership is underpinned by a highly advanced healthcare infrastructure, high levels of digital health literacy, and the presence of industry leaders such as Abbott, Dexcom, Apple, and Medtronic in the United States. Furthermore, the early adoption of remote patient monitoring and a favorable reimbursement landscape for digital health technologies contribute to the market's dominance. Key companies in the North America market include Abbott Laboratories (U.S.), Dexcom, Inc. (U.S.), Apple Inc. (U.S.), Medtronic plc (Ireland), Garmin Ltd. (U.S.), Google LLC (Fitbit - U.S.), Masimo Corporation (U.S.), VitalConnect, Inc. (U.S.), and Biolinq Inc. (U.S.). Asia-Pacific is projected to witness the fastest growth during the forecast period. This expansion is primarily driven by increasing healthcare expenditure, the rapid expansion of the middle-class population, and the high penetration of smartphones and wearable devices in China, India, and Japan. Furthermore, the rising burden of chronic diseases in the region and government initiatives to promote digital health are significant catalysts. Key companies in the Asia-Pacific market include Samsung Electronics Co., Ltd. (South Korea) and various emerging local MedTech startups. Europe remains a critical market for wearable biosensors, characterized by a strong focus on preventive healthcare and the implementation of robust medical device regulations. European countries are increasingly adopting wearable sensors to address the healthcare needs of an aging population and to improve the efficiency of public health systems. The region's focus on data privacy and security is driving the demand for sensors that comply with strict GDPR and MDR standards. Key companies in the Europe market include F. Hoffmann-La Roche Ltd. (Switzerland), Oura Health Ltd. (Finland), and Empatica Inc. (U.S./Italy). Latin America is an emerging market for wearable biosensors, driven by the modernization of healthcare facilities and the increasing adoption of consumer health technologies in Brazil and Mexico. The region is seeing a shift toward more accessible health monitoring solutions as enterprises and individuals seek to manage chronic conditions more effectively. The Middle East & Africa region is experiencing growing interest in wearable biosensors as part of national digital health transformation strategies, particularly in the UAE and Saudi Arabia. Investments in high-tech healthcare infrastructure and the adoption of AI-driven health solutions are expected to be major drivers of market growth in the region. Key Players The key players operating in the global wearable biosensors market include:
- Mexico Biobanking Market Projected to Reach USD 1.57 Billion by 2034, Driven by Precision Medicine, Genomics Research and Expanding Healthcare InvestmentsMexico’s biobanking sector is advancing through genomic initiatives, precision medicine demand, and modern automation, storage, and data systems, creating research and therapeutic opportunities